Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial

Richard J. Russell, Latifa Chachi, J. Mark FitzGerald, Vibeke Backer, Ronald Olivenstein, Ingrid L. Titlestad, Charlotte Suppli Ulrik, Timothy Harrison, Dave Singh, Rekha Chaudhuri, Brian Leaker, Lorcan McGarvey, Salman Siddiqui, Millie Wang, Martin Braddock, Lars H. Nordenmark, David Cohen, Himanshu Parikh, Gene Colice, Christopher E. Brightling*Michel Laviolette, Tina Skjold, Læge Carl Nielsen, Peter Howarth

*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

238 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences